{
  "name": "XVIVO Perfusion",
  "slug": "xvivo-perfusion",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-05T23:46:00Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-05: stängning 264.00, volym 50556",
  "mfn_status": "retrieved",
  "mfn_count": 4,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/xvivo-perfusion/reports",
    "count": 17,
    "nasdaq_count": 17,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q2",
        "period_label": "2026 Q2",
        "date": "2026-07-14",
        "title": "Kvartalsrapport Q2 2026",
        "original_title": "Delårsrapport januari - juni 2026",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b0b5abbcfdd4cd40798dae4c97bcff593&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
            "title": "Kvartalsrapport Q2 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0680c241d076247be055e08da27e968d",
            "date": "2026-07-14",
            "period": "2026-q2",
            "form_type": "interim-report",
            "report_key": "2026:q2",
            "filename": "XVIVO_Delarsrapport_Januari_Juni_2026.pdf",
            "text_chars": 79405,
            "sha256": "8bffac95165c5c8b26a6ba714b0d207045823072c1bdc2848938ba7a2f567499",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
                "chars": 79405
              }
            ]
          }
        ],
        "alternatives": [
          {
            "source": "MFN fallback",
            "language": "sv",
            "title": "Delårsrapport januari - juni 2026",
            "release_url": "https://mfn.se/a/xvivo-perfusion/delarsrapport-januari-juni-2026"
          },
          {
            "source": "MFN fallback",
            "language": "sv",
            "title": "Telefonkonferens avseende delårsrapport april-juni 2026",
            "release_url": "https://mfn.se/a/xvivo-perfusion/telefonkonferens-avseende-delarsrapport-april-juni-2026"
          }
        ]
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-04-24",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Delårsrapport januari - mars 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=baa5bcbc3fc307ce23f0fdb57d979b599&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a941583dc581b0dbcdcc0aea16c08ba15",
            "date": "2026-04-24",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "XVIVO_Delarsrapport_Q1_2026.pdf",
            "text_chars": 68483,
            "sha256": "078f9acc5643a946b13bcf798e7c5bdb9f62511784342e23069ab0140b8888ce",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 68483
              }
            ]
          }
        ],
        "alternatives": [
          {
            "source": "MFN fallback",
            "language": "sv",
            "title": "Delårsrapport januari - mars 2026",
            "release_url": "https://mfn.se/a/xvivo-perfusion/delarsrapport-januari-mars-2026"
          },
          {
            "source": "MFN fallback",
            "language": "sv",
            "title": "Telefonkonferens avseende delårsrapport januari-mars 2026",
            "release_url": "https://mfn.se/a/xvivo-perfusion/telefonkonferens-avseende-delarsrapport-januari-mars-2026"
          }
        ]
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-01",
        "title": "Årsredovisning 2025",
        "original_title": "Årsredovisning 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7bdf0373745ab8206612b6c745615d4e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a615f74af236f4a6f9efc8f84ec007fd2",
            "date": "2026-04-01",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf",
            "text_chars": 297663,
            "sha256": "32699933fab9b80e4730f5b5cbafc1a712cdd995bc233a139d2d379038636a3d",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 179473
              },
              {
                "number": 2,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 118188
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-01-27",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Bokslutskommuniké 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbf1e323680987107e9ade3e78893dd7b&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aab3317c3c213f82c4959f115aec7047b",
            "date": "2026-01-27",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "XVIVO_Bokslutskommunike_2025.pdf",
            "text_chars": 84932,
            "sha256": "be70920de31e7ac3a3e270360657c3be51e0ce8aff4d9076895aaafd02388adf",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 84932
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-10-23",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Delårsrapport januari - september 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb846263b20d9eb4e5735e73b7f34e05c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6083fd0d00915dbdf5eb7c7061d09e71",
            "date": "2025-10-23",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "XVIVO_Delarsrapport_Q3_2025.pdf",
            "text_chars": 88291,
            "sha256": "4c2f06df608966130ce293f0bf24c6ded2a92cdad0c28e048797bd1fc616aaf2",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 88291
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-07-11",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Delårsrapport januari-juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5e08de572f10d1b46f1f1504c3ed95ca&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac2517d0001a6275598b4a18f26df418f",
            "date": "2025-07-11",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "XVIVO_Delarsrapport_Q2_2025.pdf",
            "text_chars": 83790,
            "sha256": "9ca6c576f22c5d350885f34533cf2db39c3cd319d9ff9ef814cedf466f94ba27",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 83790
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-04-24",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Delårsrapport januari-mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf195a344a886c58b9323b9e085ea0189&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0630e41971a7e7f83d3e62a07a7dd3b4",
            "date": "2025-04-24",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "XVIVO_Delarsrapport_Q1_2025.pdf",
            "text_chars": 70692,
            "sha256": "58b696e541849758b47240a3be059d9cee3d470c19393430a39a15701c5de5a0",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 70692
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-02",
        "title": "Årsredovisning 2024",
        "original_title": "Årsredovisning 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b038f773b17cd4567da77aeb392d6fe21&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a479f81637801444ef3fec443441821b6",
            "date": "2025-04-02",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf",
            "text_chars": 309968,
            "sha256": "e009304fe3af6debb56cf1237544516db5b42015773d9272b02295c98cd55975",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 178215
              },
              {
                "number": 2,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 131751
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-01-28",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Bokslutskommuniké 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4a0c118a9f163b9f0d600cee15ee0e45&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a3fca5cd2988e9f95e40dcea4b9ae30c1",
            "date": "2025-01-28",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "XVIVO_Bokslutskommunike_2024.pdf",
            "text_chars": 98297,
            "sha256": "18d8631ba7e30d2b81ea8cbe5d327551e3a610d98a87d0f1098e0553a520d40c",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 98297
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-10-24",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Delårsrapport januari-september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b9d7a92cabb120715b62146a39a9c4dd9&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aafd86ee6455d0f214bead4e7b87db27d",
            "date": "2024-10-24",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "XVIVO_Delarsrapport_Januari_September_2024.pdf",
            "text_chars": 93302,
            "sha256": "6d244769370a20ed82430da4bf230cb52faf47597c0a042d254b43e919d65117",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 93302
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-07-12",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Delårsrapport januari - juni 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be961082034cceda71a6bd987a87c6201&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae4bc39452b8c18d57d41d1a3d79b4dd3",
            "date": "2024-07-12",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "XVIVO_Delarsrapport_Q2_2024.pdf",
            "text_chars": 84644,
            "sha256": "c8646a6f2eeaf79da17e0c576eb1caaa49ef7226b8b46765c02aa7700fada482",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 84644
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-04-24",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Delårsrapport januari-mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4f1d0d88309037de861a05447499097e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afd08b19f207c3c067419219657cee68a",
            "date": "2024-04-24",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "XVIVO_Delarsrapport_Q1_2024.pdf",
            "text_chars": 73866,
            "sha256": "07e7c535f884c16dcee0b372ced28af7741716c998b9b8288ffd6d6d277a0c87",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 73866
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-04-04",
        "title": "Årsredovisning 2023",
        "original_title": "Årsredovisning 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b27aec971d18b8113be546f58ba6a73c3&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/adb17d80609340e8198aeadcdb3edac22",
            "date": "2024-04-04",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf",
            "text_chars": 328330,
            "sha256": "a966b828525b8879f5bce518b9e132e61bbb641a3d838f80a85244b8ac8c5acb",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 176290
              },
              {
                "number": 2,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 152038
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-01-25",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "XVIVO avlämnar Bokslutskommuniké 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba63cd9fd99559986b54b95d5b2a3b032&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9f7506bf556d77c16fc28778ffd31219",
            "date": "2024-01-25",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "XVIVO_Bokslutskommunike_2023.pdf",
            "text_chars": 102592,
            "sha256": "0c2d8c4e7dfaee195a580c9dabbcf0996d49aa0f4fc6e7c5563dc388014a2c3a",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 102592
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-10-24",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Delårsrapport januari-September 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4caeb20a26fd9f1b2dfaad1117675c68&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a945137115ed567efad38b5e038ff0c75",
            "date": "2023-10-24",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "XVIVO_Delarsrapport_Januari_September_2023.pdf",
            "text_chars": 97520,
            "sha256": "6f9acea7642de192e012480e7d1d576d625601d3911a15461a49342a64288a45",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 97520
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-07-13",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "XVIVO avlämnar delårsrapport januari-juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bcc1abc698b1d0ec4edb416453c715854&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a07f7d275af50fb575d75dd0872902212",
            "date": "2023-07-13",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "XVIVO_Delarsrapport_Januari_Juni_2023.pdf",
            "text_chars": 88874,
            "sha256": "a9fb480625eb2301c97255699c01b78794f8c9d63c2c0c9f534a23378ec8d359",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 88874
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-04-24",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "XVIVO avlämnar delårsrapport januari-mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba839d0df61e44949f3a88008d3e007b3&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a01a8f1549d0c7ef8ac32bacf15691322",
            "date": "2023-04-24",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "XVIVO_Delarsrapport_Q1_2023.pdf",
            "text_chars": 71155,
            "sha256": "52cffa027d836b5446c9f546895c872a7b1d3b202caf8749688a45ae46a10345",
            "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 71155
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 17,
  "nasdaq_report_count": 17,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "XVIVO Perfusion",
    "identity": {
      "issuer": "Xvivo Perfusion Aktiebolag",
      "lei": "549300G2464FYLS14B41",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 15,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "XVIVO Perfusion",
      "query": "Xvivo Perfusion Aktiebolag",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-04",
      "to": "2026-08-04",
      "years": 2
    },
    "generated_at": "2026-08-04T20:08:25Z",
    "insider": {
      "transactions": 14,
      "all_export_rows": 14,
      "acquisitions": 10,
      "disposals": 4,
      "other": 0,
      "acquisition_value_sek": 3013720.0,
      "disposal_value_sek": 1874700.0,
      "characters": {
        "Avyttring": 4,
        "Förvärv": 10
      }
    },
    "short_selling": {
      "aggregate_percent": 9.16,
      "current_public_positions": 6,
      "historical_changes": 157,
      "current_position_sum_over_0_5": 5.61
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "xvivo",
      "instrument_id": "TX1194230",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xvivo?id=TX1194230"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "XVIVO Perfusion AB",
      "expected_name": "XVIVO Perfusion",
      "match_score": 100.0,
      "slug": "xvivo-perfusion",
      "url": "https://mfn.se/all/a/xvivo-perfusion",
      "metadata": {
        "country": "Sverige",
        "list": "Mid Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Medicinteknik",
        "website": "https://career.modularfinance.se"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX1194230",
      "asset_class": "SHARES",
      "isin": "SE0004840718",
      "symbol": "XVIVO",
      "company": "Xvivo Perfusion",
      "market": null,
      "last_sale_price": "SEK 264.00",
      "time_as_of": "2026-08-05"
    },
    "finansinspektionen": {
      "issuer": "Xvivo Perfusion Aktiebolag",
      "lei": "549300G2464FYLS14B41",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 15,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "XVIVO Perfusion",
      "query": "Xvivo Perfusion Aktiebolag",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
      "title": "Kvartalsrapport Q2 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0680c241d076247be055e08da27e968d",
      "date": "2026-07-14",
      "period": "2026-q2",
      "form_type": "interim-report",
      "report_key": "2026:q2",
      "filename": "XVIVO_Delarsrapport_Januari_Juni_2026.pdf",
      "text_chars": 79405,
      "sha256": "8bffac95165c5c8b26a6ba714b0d207045823072c1bdc2848938ba7a2f567499",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
          "chars": 79405
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a941583dc581b0dbcdcc0aea16c08ba15",
      "date": "2026-04-24",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "XVIVO_Delarsrapport_Q1_2026.pdf",
      "text_chars": 68483,
      "sha256": "078f9acc5643a946b13bcf798e7c5bdb9f62511784342e23069ab0140b8888ce",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 68483
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a615f74af236f4a6f9efc8f84ec007fd2",
      "date": "2026-04-01",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "XVIVO_Perfusion_Ab_publ_Arsredovisning_2025.pdf",
      "text_chars": 297663,
      "sha256": "32699933fab9b80e4730f5b5cbafc1a712cdd995bc233a139d2d379038636a3d",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 179473
        },
        {
          "number": 2,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 118188
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aab3317c3c213f82c4959f115aec7047b",
      "date": "2026-01-27",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "XVIVO_Bokslutskommunike_2025.pdf",
      "text_chars": 84932,
      "sha256": "be70920de31e7ac3a3e270360657c3be51e0ce8aff4d9076895aaafd02388adf",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 84932
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6083fd0d00915dbdf5eb7c7061d09e71",
      "date": "2025-10-23",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "XVIVO_Delarsrapport_Q3_2025.pdf",
      "text_chars": 88291,
      "sha256": "4c2f06df608966130ce293f0bf24c6ded2a92cdad0c28e048797bd1fc616aaf2",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 88291
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac2517d0001a6275598b4a18f26df418f",
      "date": "2025-07-11",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "XVIVO_Delarsrapport_Q2_2025.pdf",
      "text_chars": 83790,
      "sha256": "9ca6c576f22c5d350885f34533cf2db39c3cd319d9ff9ef814cedf466f94ba27",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 83790
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0630e41971a7e7f83d3e62a07a7dd3b4",
      "date": "2025-04-24",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "XVIVO_Delarsrapport_Q1_2025.pdf",
      "text_chars": 70692,
      "sha256": "58b696e541849758b47240a3be059d9cee3d470c19393430a39a15701c5de5a0",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 70692
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a479f81637801444ef3fec443441821b6",
      "date": "2025-04-02",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2024.pdf",
      "text_chars": 309968,
      "sha256": "e009304fe3af6debb56cf1237544516db5b42015773d9272b02295c98cd55975",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 178215
        },
        {
          "number": 2,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 131751
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a3fca5cd2988e9f95e40dcea4b9ae30c1",
      "date": "2025-01-28",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "XVIVO_Bokslutskommunike_2024.pdf",
      "text_chars": 98297,
      "sha256": "18d8631ba7e30d2b81ea8cbe5d327551e3a610d98a87d0f1098e0553a520d40c",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 98297
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aafd86ee6455d0f214bead4e7b87db27d",
      "date": "2024-10-24",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "XVIVO_Delarsrapport_Januari_September_2024.pdf",
      "text_chars": 93302,
      "sha256": "6d244769370a20ed82430da4bf230cb52faf47597c0a042d254b43e919d65117",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 93302
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae4bc39452b8c18d57d41d1a3d79b4dd3",
      "date": "2024-07-12",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "XVIVO_Delarsrapport_Q2_2024.pdf",
      "text_chars": 84644,
      "sha256": "c8646a6f2eeaf79da17e0c576eb1caaa49ef7226b8b46765c02aa7700fada482",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 84644
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afd08b19f207c3c067419219657cee68a",
      "date": "2024-04-24",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "XVIVO_Delarsrapport_Q1_2024.pdf",
      "text_chars": 73866,
      "sha256": "07e7c535f884c16dcee0b372ced28af7741716c998b9b8288ffd6d6d277a0c87",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 73866
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/adb17d80609340e8198aeadcdb3edac22",
      "date": "2024-04-04",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "XVIVO_Perfusion_AB_publ_Arsredovisning_2023.pdf",
      "text_chars": 328330,
      "sha256": "a966b828525b8879f5bce518b9e132e61bbb641a3d838f80a85244b8ac8c5acb",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 176290
        },
        {
          "number": 2,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 152038
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9f7506bf556d77c16fc28778ffd31219",
      "date": "2024-01-25",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "XVIVO_Bokslutskommunike_2023.pdf",
      "text_chars": 102592,
      "sha256": "0c2d8c4e7dfaee195a580c9dabbcf0996d49aa0f4fc6e7c5563dc388014a2c3a",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 102592
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a945137115ed567efad38b5e038ff0c75",
      "date": "2023-10-24",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "XVIVO_Delarsrapport_Januari_September_2023.pdf",
      "text_chars": 97520,
      "sha256": "6f9acea7642de192e012480e7d1d576d625601d3911a15461a49342a64288a45",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 97520
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a07f7d275af50fb575d75dd0872902212",
      "date": "2023-07-13",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "XVIVO_Delarsrapport_Januari_Juni_2023.pdf",
      "text_chars": 88874,
      "sha256": "a9fb480625eb2301c97255699c01b78794f8c9d63c2c0c9f534a23378ec8d359",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 88874
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a01a8f1549d0c7ef8ac32bacf15691322",
      "date": "2023-04-24",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "XVIVO_Delarsrapport_Q1_2023.pdf",
      "text_chars": 71155,
      "sha256": "52cffa027d836b5446c9f546895c872a7b1d3b202caf8749688a45ae46a10345",
      "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 71155
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/xvivo-perfusion",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 13628,
      "sha256": "efd4a31f9f69198fa818c805ade7fb1fcfa565a9072c06b54968c5e9af68d0a1",
      "url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xvivo-perfusion/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 13628
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/xvivo-perfusion/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/xvivo-perfusion/market/history.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/xvivo-perfusion/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/xvivo-perfusion/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/instrument.json"
    },
    {
      "label": "SEC sammanfattning JSON",
      "url": "/company/xvivo-perfusion/market/sec-summary.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/sec-summary.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/xvivo-perfusion/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/xvivo-perfusion/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xvivo-perfusion/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": true,
    "status": "retrieved",
    "captured_at": "2026-08-01T06:08:57Z",
    "view_count": 4,
    "url": "/company/xvivo-perfusion/morningstar",
    "path": "D:\\Web\\aktieanalys\\public\\company\\.xvivo-perfusion.tmp\\morningstar",
    "files": [
      "index.html",
      "summary.txt",
      "screenshot.png"
    ]
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/xvivo-perfusion/finansinspektionen",
    "transaction_count": 14,
    "aggregate_short_percent": 9.16,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/xvivo-perfusion/llms.txt",
  "json_url": "/company/xvivo-perfusion/company.json",
  "document_index_url": "/company/xvivo-perfusion/documents.json",
  "absolute_url": "https://spela.port0.org/company/xvivo-perfusion"
}